Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
NCT04991103
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
Doctors are conducting a study for patients with multiple myeloma, a type of cancer. They want to see if using a special test to look for leftover cancer cells after treatment can help decide if patients need a transplant. The transplant is when the patient gets their own stem cells back to help their body fight the cancer. The doctors hope this test can help some patients avoid the transplant.
Doctors are conducting a study for patients with multiple myeloma, a type of cancer. They want to see if using a special test to look for leftover cancer cells after treatment can help decide if patients need a transplant. The transplant is when the patient gets their own stem cells back to help their body fight the cancer. The doctors hope this test can help some patients avoid the transplant.
Third Opinion AI Generated Synopsis
Trial Summary
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
